Pharmacokinetic Profile of MGCD 265, an Oral Tyrosine Kinase Inhibitor, with or Without Food in Healthy Volunteers

Trial Profile

Pharmacokinetic Profile of MGCD 265, an Oral Tyrosine Kinase Inhibitor, with or Without Food in Healthy Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 02 Nov 2012

At a glance

  • Drugs Glesatinib (Primary)
  • Indications Gastric cancer; Non-small cell lung cancer; Prostate cancer; Solid tumours
  • Focus Pharmacokinetics
  • Sponsors MethylGene
  • Most Recent Events

    • 02 Nov 2012 New trial record
    • 01 Oct 2012 Results presented at the 37th Congress of the European Society for Medical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top